Myriad stumbles, Wyeth closes on Alzheimer's

Recently, the race for a first-in-class therapy for Alzheimer's disease lost front-runner Myriad and saw Wyeth up the pace with preliminary phase 2 results for its lead candidate, bapineuzumab, a humanized monoclonal antibody (mAb) that is already under phase 3 development. But with several con...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2008-08, Vol.26 (8), p.841-843
1. Verfasser:	Osborne, Randy
Format:	Artikel
Sprache:	eng
Schlagworte:	Agriculture Alzheimer Disease - drug therapy Alzheimer's disease Antibodies, Monoclonal - therapeutic use Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Competition Dosage and administration Drug Design Drug Industry Drug therapy Health aspects Humans Inhibitor drugs Life Sciences Monoclonal antibodies news Pharmaceutical industry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recently, the race for a first-in-class therapy for Alzheimer's disease lost front-runner Myriad and saw Wyeth up the pace with preliminary phase 2 results for its lead candidate, bapineuzumab, a humanized monoclonal antibody (mAb) that is already under phase 3 development. But with several contenders in the pipeline, predicting winners in Alzheimer's disease continues to be challenging.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt0808-841